O SlideShare utiliza cookies para otimizar a funcionalidade e o desempenho do site, assim como para apresentar publicidade mais relevante aos nossos usuários. Se você continuar a navegar o site, você aceita o uso de cookies. Leia nosso Contrato do Usuário e nossa Política de Privacidade.
O SlideShare utiliza cookies para otimizar a funcionalidade e o desempenho do site, assim como para apresentar publicidade mais relevante aos nossos usuários. Se você continuar a utilizar o site, você aceita o uso de cookies. Leia nossa Política de Privacidade e nosso Contrato do Usuário para obter mais detalhes.
Product Name: AlcepidSalt & Composition: Cefpodoxime Proxetil 100mg/200mgMode of Actions: Cefpodoxime is an oral third generation cephalosporin antibiotic. Cefpodoxime fights bacteria in thebody. It is active against most Gram positive and Gram negative bacteriaCefpodoxime proxetil is a prodrug which isabsorbed and de-esterified by the intestinal mucosa to Cefpodoxime.Pharmacokinetic Action: Cefpodoxime proxetil is an orally administered, extended-spectrum, semi-syntheticantibiotic of the cephalosporin class. Cefpodoxime is stable in the presence of betalactamase enzymes. As a result,many organisms resistant to penicillins and cephalosporins, due to their production of beta-lactamase, may besusceptible to cefpodoxime. Cefpodoxime is inactivated by certain extended-spectrum betalactamases. Thebactericidal activity of cefpodoxime results from its inhibition of cell wall synthesis.Drug Class and Mechanism: Broad and medium spectrum antibiotics. Cefpodoxime is an antibiotic in a class of drugscalled cephalosporins. Cefpodoxime proxetil is a semi-synthetic beta-lactam antibiotic belonging to the thirdgeneration oral cephalosporin group. Cefpodoxime proxetil is the prodrug of the bactericidal antibiotic cefpodoxime.The antibacterial action of cefpodoxime is through inhibition of bacterial cell wall synthesis probably by acylation ofmembrane bound transpeptidase enzymes; this prevents cross linkage of peptidoglycan chains, which is necessary forbacterial cell wall strength and rigidity.Prescribed For: many different types of bacterial infections such as bronchitis, pneumonia, tonsillitis, ear infections,sinus infections, skin infections, gonorrhea, and urinary tract infections. It is commonly used to treat acute otitismedia, pharyngitis, and sinusitis.Mode of use: Take this medicine by mouth after food with a full glass of water. It is recommended to take themedicine at regular intervals. Take the medicine as directed by the physician. Do not skip doses or stop your medicineearly.Dosage: As directed by the physician. The recommended dosage and duration of treatment in adults may vary from200mg to 800mg per day for 5-14 days depending on the type and severity of the infection as per the following chart:
In case of a missed dose: If you miss a dose, take it as soon as you can. If it is almost time for your next dose, takeonly that dose. Do not take double or extra doses. There should be an interval of at least 12 hours between doses.Interaction: Cefpodoxime proxetil is contra-indicated in patients who are allergic to cefpodoxime or to cephalosporingroup of antibiotics. Safety of cefpodoxime proxetil for use in pregnancy and lactation has not been established.Some of the diuretics, antacids, medicines for stomach acid or ulcer and sodium bicarbonate may interfere with theperformance of Cefpodoxime. Hence its advisable to inform your doctor in advance about all the other medicinesbeing taken. Smoking, caffine and use of alcohol can also affect the outcome of the drug use.Side effects: Side effects that you should report to your doctor as soon as possible include allergic reactions like skinrash, itching, swelling of the face, lips, or tongue, breathing problems, fast, irregular heartbeat, redness, blistering,peeling or loosening of the skin, including inside the mouth and unusually weakness or tiredness.Packaging: Each box contains 1 strip of 10 tablets eachNEWS HIGHLIGHTSMedia Articles Related to Floxin (Ofloxacin)Aradigm Reports Successful Phase 2b Bronchiectasis Study With Inhaled Liposomal CiprofloxacinSource: Cystic Fibrosis News From Medical News Today [2010.10.22]Aradigm Corporation (OTCBB:ARDM) (the "Company") announced positive top line data from itsrecently concluded 6-month Phase 2b study (ORBIT-2) with Aradigms once-daily dual releaseciprofloxacin for inhalation (DRCFI, ARD-3150) in patients with non-cystic fibrosis bronchiectasis.Statistical significance was achieved in the primary endpoint and one of the secondary endpoints...
ciprofloxacin ointment - ophthalmic, CiloxanSource: MedicineNet ciprofloxacin Specialty [2010.09.22]Title: ciprofloxacin ointment - ophthalmic, CiloxanCategory: MedicationsCreated: 3/2/2005Last Editorial Review: 9/22/2010ciprofloxacin/hydrocortisone suspension - otic, Cipro HCSource: MedicineNet ciprofloxacin Specialty [2010.09.22]Title: ciprofloxacin/hydrocortisone suspension - otic, Cipro HCCategory: MedicationsCreated: 3/2/2005Last Editorial Review: 9/22/2010ciprofloxacin drops - ophthalmic, CiloxanSource: MedicineNet ciprofloxacin Specialty [2010.09.22]Title: ciprofloxacin drops - ophthalmic, CiloxanCategory: MedicationsCreated: 3/2/2005Last Editorial Review: 9/22/2010ciprofloxacin/dexamethasone suspension - otic, CiprodexSource: MedicineNet levofloxacin Specialty [2010.09.22]Title: ciprofloxacin/dexamethasone suspension - otic, CiprodexCategory: MedicationsCreated: 3/2/2005Last Editorial Review: 9/22/2010 more news >>Published Studies Related to Floxin (Ofloxacin)Safety and efficacy of levofloxacin 750 mg for 2 weeks or 3 weeks compared with levofloxacin 500mg for 4 weeks in treating chronic bacterial prostatitis. [2010.06]CONCLUSIONS: Higher doses for shorter durations were determined to be no worse than standardtherapy with levofloxacin 500 mg for a longer duration at the TOC visit. However, at the 6-monthfollow-up visit, the levofloxacin 750-mg dose administered for either 2 weeks or 3 weeks wasinferior to the standard therapy, suggesting that a longer duration of treatment may help extend therelapse-free interval in patients with CBP. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov,nct00402688.Pharmacokinetics of antofloxacin hydrochloride, a novel fluoroquinolone, after single-doseintravenous administration in healthy Chinese male volunteers. [2010.05]The purpose of the study was to evaluate the pharmacokinetic characteristics of a single,intravenous dose of antofloxacin hydrochloride in healthy Chinese male volunteers. Twelve
subjects were randomly assigned to groups that received a single, intravenous dose of 200, 300, or400 mg antofloxacin hydrochloride in a three-way crossover design study...Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia. [2010.04]BACKGROUND: Community-acquired pneumonia (CAP) affects 5-10 million adults annually inthe United States with approximately 1.1 million hospitalizations. Current guidelines recommendfluoroquinolones as monotherapy for treatment of CAP in general medical wards and doxycyclinemonotherapy for outpatient therapy only. Fluoroquinolones are expensive and development ofbacterial resistance to them has become a concern. Therefore, we studied whether doxycycline is asefficacious as levofloxacin in treatment of CAP in general medical wards... CONCLUSIONS: Ourstudy supports doxycycline as an effective and economical alternative therapy for levofloxacin inthe empirical treatment of CAP in general medical wards.Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthyvolunteers. [2010.04]AIMS: To characterize the effects of levofloxacin on QT interval in healthy subjects and the mostappropriate oral positive control treatments for International Conference on Harmonization (ICH)E14 QT/QTc studies... CONCLUSIONS: Both levofloxacin and moxifloxacin can fulfil the criteriafor a positive comparator. The ICH E14 guidelines recommend a threshold of around 5 ms for apositive QT/QTc study. The largest time-matched difference in QTc for levofloxacin suggests thepotential for use in more rigorous QT/QTc studies. This study has demonstrated the utility oflevofloxacin on the assay in measuring mean QTc changes around 5 ms.A randomized controlled trial: efficacy and safety of azithromycin, ofloxacin, bismuth, andomeprazole compared with amoxicillin, clarithromycin, bismuth, and omeprazole as second-linetherapy in patients with Helicobacter pylori infection. [2010.04]BACKGROUND: Helicobacter pylori infection of the stomach is widespread among humanpopulations and is considered to play a major role in the pathogenesis of various diseases such aspeptic ulcer, adenocarcinoma, and mucosa associated lymphoid tissue (MALT) lymphoma of thestomach. To increase H. pylori eradication rate without increasing bacterial resistance, variousregimens have been recommended. Commonly the association of at least two antibiotics with aproton-pump inhibitor is used. The treatment regimens for second-line therapy, suggested in studiesfrom the western world may not be ideal in Iran. Aim: In this study, we evaluated the safety andefficacy of a new quadruple therapy regimen and compared it with the standard second-linetreatment for H. pylori eradication... CONCLUSION: Two weeks of treatment with ofloxacin,azithromycin, omeprazole, and bismuth is an effective and safe regimen for H. pylori eradication assecond-line therapy. more studies >>Clinical Trials Related to Floxin (Ofloxacin)An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis [Active, not recruiting]The purpose of this study is to compare the safety and effectiveness of levofloxacin 750 mg for 2weeks or 750 mg for 3 weeks, compared to levofloxacin 500 mg for 4 weeks in the treatment ofchronic prostatitis.
MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers[Completed]224 adults with diabetic foot ulcers will be randomized to either magainin peptide (MSI-78) orofloxacin (FLOXIN, Ortho-McNeil Pharmaceutical Corporation) an oral fluoroquinolone antibiotic.MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers[Completed]224 adults with diabetic foot ulcers will be randomized to either magainin peptide (MSI-78) orofloxacin (FLOXIN, Ortho-McNeil Pharmaceutical Corporation) an oral fluoroquinolone antibiotic.A Study to Evaluate the Bioequivalence of an Oral Suspension Formulation, an Oral SolutionFormulation, and the Marketed Tablet Formulation of Levofloxacin in Healthy Subjects[Completed]The primary objective of the study was to assess the bioequivalence of the oral suspensionformulation, the oral solution formulation, and the marketed tablet formulation of levofloxacin, withthe marketed tablet as the reference.Study of Efficacy of Levofloxacin 0.5% Ophthalmic Solution Administered Three Times a Day forBacterial Conjunctivitis [Completed]The aim of the study is to evaluate the clinical and microbiological efficacies of three times dailyadministration of levofloxacin 0,5% eye drops as compared to the more frequent dosing (up to 8times a day during the first 2 days and up to 4 times a day during the next 3 days) in patients withbacterial conjunctivitis. more trials >>